Effects of Imatinib Mesylate in Polycythemia Vera

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single agent, in inducing a haematological response in Polycythemia Vera.

The patients will be asked to have additional bone marrow and blood samples collected: these samples will be used to evaluate how the disease is responding to the drug.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Niguarda Hospital
• Treatments: Imatinib Mesylate

Criteria

Inclusion Criteria:

• Diagnosis of Polycythemia Vera requiring treatment with either phlebotomy or Hydroxyurea

• Age >18 years

• Signed written informed consent form

Exclusion Criteria:

• Pregnancy or breast-feeding

• Creatinine >3 max NV

• Bilirubin >3 max NV

• AST/ALT >3 max NV

• Concomitant and severe psychiatric disorder

• Concomitant neoplastic disease